La Jolla Pharmaceutical Co

La Jolla Pharmaceutical — Investor Presentation (July 2015)

31 slides from La Jolla Pharmaceutical's investor presentation, Jul 27, 2015

  1. Slide 1: Developing Innovative Therapies for Patients Suffering from Life-threatening Diseases

    July 2015 Developing Innovative Therapies for Patients Suffering from Life-threatening Diseases NASDAQ: LJPC

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements These slides contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking terminology such as "anticipate", "believe", "continue", "could", "estimate", "exp

  3. Slide 3: Overview of LJPC

    Overview of LJPC LJPC-501 (Angiotensin II) for CRH LJPC-401 (Hepcidin) for HH LJPC-30Sa/b (Gentamicin Derivatives) for Bacterial Infections and Rare Genetic Disorders Financial Position

  4. Slide 4: Mission Statement

    Mission Statement La Jolla is dedicated to improving the lives of patients suffering from life- threatening diseases by discovering and developing innovative therapies 4

  5. Slide 5: LJPC Corporate Highlights

    LJPC Corporate Highlights • Focused on de-risked product opportunities  Naturally occurring peptides with well-understood biological functions  Derivative components of FDA-approved products • LJPC-501 (angiotensin II) for catecholamine-resistant hypotension (CRH)  Phase 3 registration study acti

  6. Slide 6: Product Pipeline

    Product Pipeline LJPC-501 Angiotensin II LJPC-401 Hepcidin Other R&D Indication IND Phase 1 Phase 2 Phase 3 UnderwayCompleted Planned HRS CRH End 2015 Various H2 2016 HH Phase 1/2 Mid- 2015 LJPC-30Sa & LJPC-30Sb Gentamicin Derivatives Bacterial Infections Rare Genetic Disorders Galectin-3 Inhibitor

  7. Slide 7: Overview of LJPC: LJPC-501

    Overview of LJPC LJPC-501 (Angiotensin II) for CRH LJPC-401 (Hepcidin) for HH LJPC-30Sa/b (Gentamicin Derivatives) for Bacterial Infections and Rare Genetic Disorders Financial Position

  8. Slide 8: LJPC-501: Overview

    LJPC-501: Overview • LJPC-501 is a proprietary formulation of angiotensin II, a naturally occurring regulator of blood pressure • Catecholamine-resistant hypotension (CRH) is an acute, life-threatening condition in which blood pressure drops to dangerously low levels and is unresponsive to current t

  9. Slide 9: Three Systems Work in Harmony to Regulate Blood Pressure

    Three Systems Work in Harmony to Regulate Blood Pressure Current therapeutic options for the treatment of acute hypotension only leverage the adrenal system and vasopressin system The Body’s Three Systems that Regulate Blood Pressure 9

  10. Slide 10: High Doses of Catecholamines Increase Mortality

    High Doses of Catecholamines Increase Mortality 1Sviri et al, J. of Crit Care, 29;157-160, 2014 • Catecholamines (i.e., norepinephrine, epinephrine and dopamine) cause cardiac toxicity, digital necrosis and metabolic complications leading to higher mortality1 0 10 20 30 40 50 60 70 80 90 Low Dose Hi

  11. Slide 11: Norepinephrine Dose Decreases with Angiotensin II

    Norepinephrine Dose Decreases with Angiotensin II Surrogate Effect on Blood Pressure Source: Chawla et al, Critical Care, 18:534, 2014 0 5 10 15 20 25 30 35 40 45 50 Pre2 Pre1 Hr0 Hr1 Hr2 Hr3 Hr4 Hr5 Hr6 Post1 Post2 N or ep in ep hr in e D os e (m cg /m in ) Placebo AT-II Arm Angio dose placebo grou

  12. Slide 12: LJPC-501: Phase 3 Trial in CRH

    LJPC-501: Phase 3 Trial in CRH SPA Agreement with FDA Reached, Trial Enrolling • ATHOS (Angiotensin II for the Treatment of High-Output Shock) 3 trial initiated in March 2015 • Randomized, placebo-controlled, double-blind Phase 3 trial • Patient population: catecholamine-resistant, based on amount o

  13. Slide 13: LJPC-501: Market Opportunity - Large Target Population

    LJPC-501: Market Opportunity Large Target Population Total Annual Hospitalized U.S. Population with Severe Hypotension Applicable Severe Hypotension: 65% Catecholamine-Treated Patients: 92% Catecholamine-Resistant* Patients: 38% LJPC-501 Target Market 555,479 361,684 332,189 126,232 *Catecholamine-r

  14. Slide 14: LJPC-501: Market Opportunity - Attractive Pricing Potential

    LJPC-501: Market Opportunity Attractive Pricing Potential Prices of Hospital-Based Drugs Reimbursed under DRGs Source: Wolters Kluwer PriceRx Pro, product package inserts, IMS Health inpatient/outpatient hospital charge master Catecholamine-Resistant* Catecholamine-Responsive Average total cost per

  15. Slide 15: LJPC-501: Market Opportunity - Strong Interest

    LJPC-501: Market Opportunity Strong Interest Even among P&T Decision Makers Robust (N=100) survey of physicians, 50% of which are P&T decision makers, shows strong interest based on evidence in primary endpoint alone Source: IMS Health survey, 2015 Endpoints Achieved Scenario 1 Scenario 2 Scenario 3

  16. Slide 16: Summary of LJPC-501

    Summary of LJPC-501 • LJPC-501 is a proprietary formulation of angiotensin II, a naturally occurring regulator of blood pressure • Catecholamine-resistant hypotension (CRH) is an acute, life-threatening condition in which blood pressure drops to dangerously low levels and is unresponsive to current

  17. Slide 17: Overview of LJPC: LJPC-401

    Overview of LJPC LJPC-501 (Angiotensin II) for CRH LJPC-401 (Hepcidin) for HH LJPC-30Sa/b (Gentamicin Derivatives) for Bacterial Infections and Rare Genetic Disorders Financial Position

  18. Slide 18: LJPC-401: Overview

    LJPC-401: Overview • LJPC-401 is a novel formulation of hepcidin, a naturally occurring regulator of iron absorption and distribution • Hereditary hemochromatosis (HH) is a disease characterized by a deficiency of hepcidin that results in excessive iron accumulation, which is toxic to vital organs s

  19. Slide 19: Hepcidin: The Insulin of Iron Metabolism

    Hepcidin: The Insulin of Iron Metabolism • Hepcidin: the insulin of iron metabolism  Regulates iron absorption and disposition in all organs  Rapid and sustained lowering of iron levels • Progress  SQ formulation developed  Completed toxicology • Phase 1 data in 2015  Including serum iron data

  20. Slide 20: LJPC-401: Phase 1 Development Plan

    LJPC-401: Phase 1 Development Plan • Key endpoint includes effect on serum iron levels  Early insight into LJPC-401’s efficacy using clinically relevant endpoint  Study to start in mid-2015 – results will be available by end of 2015 OBJECTIVES: determine safety of escalating doses of LJPC-401 in N

  21. Slide 21: LJPC-401: Market Overview

    LJPC-401: Market Overview • Hereditary Hemochromatosis (HH)  Most common genetic disease in Caucasians  Silent Killer - Iron accumulation can lead to liver cirrhosis, liver cancer, heart disease and/or failure, dementia and diabetes  No FDA-approved treatment  Current treatments don’t address th

  22. Slide 22: Overview of LJPC: LJPC-30Sa/b

    Overview of LJPC LJPC-501 (Angiotensin II) for CRH LJPC-401 (Hepcidin) for HH LJPC-30Sa/b (Gentamicin Derivatives) for Bacterial Infections and Rare Genetic Disorders Financial Position

  23. Slide 23: LJPC-30Sa/b: Overview

    LJPC-30Sa/b: Overview • LJPC-30Sa and LJPC-30Sb are purified derivatives of gentamicin, which retain biologic activity but lack traditional kidney toxicity • Gentamicin: FDA-approved, standard-of-care for serious Gram-negative bacterial infections  Mixture of several distinct but closely related ch

  24. Slide 24: LJPC-30Sa/b: Potential for Improved Clinical Profile

    Next-generation improved gentamicin derivative 1. Retain activity LJPC-30Sa/b: Potential for Improved Clinical Profile 2. Improve safety 0.0 4.0 8.0 12.0 16.0 placebo next-generation gentamicin derivative gentamicin In hi bi tio n/ ki ll zo ne (m m ) B.subtilus K.pneumonieae (kill) K.pneumonieae (in

  25. Slide 25: LJPC-30Sa/b: Mechanism of Action

    Gentamicin induces errors in the translation of genes into proteins Bacteria LJPC-30Sa/b: Mechanism of Action Can Be Leveraged Down Two Development Paths Alters protein synthesis leading to cell death Alters protein synthesis to allow read through of stop-codon mutations Humans 25

  26. Slide 26: LJPC-30Sa/b: Market Opportunity

    LJPC-30Sa/b: Market Opportunity • Antibiotic opportunity = $500+ million per year in U.S.  Market could expand with a safer alternative – Increased duration of therapy, increased penetration, and/or new indications • Other large potential market opportunity in rare genetic disorders, such as cystic

  27. Slide 27: LJPC-30Sa/b: Clinical Proof-of-Concept in Cystic Fibrosis

    LJPC-30Sa/b: Clinical Proof-of-Concept in Cystic Fibrosis References: Sermet-Gaudelus et al, BMC Medicine, 5:5, 2007; Wilchanski et al, NEJM, 349:1433-41, 2003; Clancy J.P. et al, Am J Respir Crit Care Med, 163:1683-1692, 2001 • Three, independent studies suggest gentamicin helps read through stop-c

  28. Slide 28: Overview of LJPC: Financial Position

    Overview of LJPC LJPC-501 (Angiotensin II) for CRH LJPC-401 (Hepcidin) for HH LJPC-30Sa/b (Gentamicin Derivatives) for Bacterial Infections and Rare Genetic Disorders Financial Position

  29. Slide 29: Financial Position

    Financial Position Cash resources expected to fund Company through 2016 Condensed Balance Sheet Data As of Mar 31, 2015 (in millions) Cash $42.7 Total liabilities $2.6 Total shareholders’ equity $43.0 Fully Diluted, As-Converted Shares Outstanding* 24,019,500 *Includes common stock, preferred stock

  30. Slide 30: LJPC Investment Summary

    LJPC Investment Summary • Focused on de-risked product opportunities  Naturally occurring peptides with well-understood biological functions  Derivative components of FDA-approved products • LJPC-501 (angiotensin II) for catecholamine-resistant hypotension (CRH)  Phase 3 registration study active

  31. Slide 31: Thank You

    : Pharmaceuti Thank You

LA Jolla Pharmaceutical — Investor Presentation (July 2015) on 6ix